ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin

Long Chen; Lei Shi; Wenhua Wang; Youxin Zhou

doi:10.18632/oncotarget.18018

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin

Long Chen, Lei Shi _, Wenhua Wang and Youxin Zhou

PDF | HTML | How to cite

Oncotarget. 2017; 8:43237-43247. https://doi.org/10.18632/oncotarget.18018

Metrics: PDF 1392 views | HTML 1971 views | ?

Abstract

Long Chen1,2,*, Lei Shi3,*, Wenhua Wang2,* and Youxin Zhou1

1Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, P. R. China

2Department of Neurosurgery, Traditional Chinese Medicine Hospital of Kunshan, Affiliated Nanjing University of Traditional Chinese Medicine, Suzhou 215300, P. R. China

3Department of Neurosurgery, The First People’s Hospital of Kunshan Affiliated with Jiangsu University, Suzhou 215300, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Lei Shi, email: [email protected]

Youxin Zhou, email: [email protected]

Keywords: glioma stem cells, demethoxycurcumin, reactive oxygen species, caspase-3, ABCG2

Received: February 20, 2017 Accepted: April 06, 2017 Published: May 19, 2017

ABSTRACT

We analyzed the role of ABCG2, a drug transporter, in determining the sensitivity of glioma stem cells (GSCs) to demethoxycurcumin (DMC). We first demonstrated that ABCG2 is more highly expressed in GSCs than primary astrocytes. Modulation of ABCG2 levels in GSCs by transfection of ABCG2 shRNA or a lentiviral vector encoding ABCG2 revealed an inverse relation between ABCG2 levels and DMC-induced GSC growth inhibition. Suppressing ABCG2 increased DMC-induced apoptosis and G0/G1 cell cycle arrest in GSCs. It also increased levels reactive oxygen species (ROS) in GSCs treated with DMC, resulting in increased cytochrome C and caspase-3 activity. When GSCs transfected with ABCG2 shRNA or overexpressing ABCG2 were xenografted and the tumor-bearing, immunodeficient mice were treated with DMC, ABCG2 expression suppressed the tumor proliferation rate (T/C %). These findings demonstrate that ABCG2 expression is critical for DMC resistance in GSCs and is a potential therapeutic target for GBM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18018

Publication Alerts

Research Papers:

ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin

Abstract